Back to the complete issue
Tuesday, 28 April 2020

Existing medication

Some research labs and pharma companies are taking a different approach and exploring whether existing medication can treat the virus. There is still no consensus, but tests have yielded some interesting results:

Remdesivir is an antiviral medication that has been used to treat Ebola: A large-scale clinical trial launched last month to test a mix of remdesivir, lopinavir and ritonavir on 3.2k patients. Tests are also ongoing in the US on the use of remdesivir after a reported two-thirds of severe covid-19 cases showed improvement when it was used.

Japanese influenza medication favipiravir has drawn praise from Chinese medical authorities: Clinical trials saw 340 patients from Wuhan and Shenzhen test negative for covid-19 in only four days but the med seems to only be effective in cases that were caught early.

Australia is testing antimalarial drug chloroquine, and HIV-suppressing combination lopinavir/ ritonavir: All cases in early clinical trials of these medications have completely recovered from covid-19. But before we follow The Donald’s lead and start touting chloroquine as a miracle covid-19 cure, it’s worth remembering that scientists have yet to draw conclusive evidence that the patients’ own immune systems were not behind the recoveries.

Enterprise is a daily publication of Enterprise Ventures LLC, an Egyptian limited liability company (commercial register 83594), and a subsidiary of Inktank Communications. Summaries are intended for guidance only and are provided on an as-is basis; kindly refer to the source article in its original language prior to undertaking any action. Neither Enterprise Ventures nor its staff assume any responsibility or liability for the accuracy of the information contained in this publication, whether in the form of summaries or analysis. © 2022 Enterprise Ventures LLC.

Enterprise is available without charge thanks to the generous support of HSBC Egypt (tax ID: 204-901-715), the leading corporate and retail lender in Egypt; EFG Hermes (tax ID: 200-178-385), the leading financial services corporation in frontier emerging markets; SODIC (tax ID: 212-168-002), a leading Egyptian real estate developer; SomaBay (tax ID: 204-903-300), our Red Sea holiday partner; Infinity (tax ID: 474-939-359), the ultimate way to power cities, industries, and homes directly from nature right here in Egypt; CIRA (tax ID: 200-069-608), the leading providers of K-12 and higher level education in Egypt; Orascom Construction (tax ID: 229-988-806), the leading construction and engineering company building infrastructure in Egypt and abroad; Moharram & Partners (tax ID: 616-112-459), the leading public policy and government affairs partner; Palm Hills Developments (tax ID: 432-737-014), a leading developer of commercial and residential properties; Mashreq (tax ID: 204-898-862), the MENA region’s leading homegrown personal and digital bank; Industrial Development Group (IDG) (tax ID:266-965-253), the leading builder of industrial parks in Egypt; Hassan Allam Properties (tax ID:  553-096-567), one of Egypt’s most prominent and leading builders; and Saleh, Barsoum & Abdel Aziz (tax ID: 220-002-827), the leading audit, tax and accounting firm in Egypt.